This compound is primarily utilized in the development of antibody-drug conjugates (ADCs), which are targeted cancer therapies. The chemical serves as a linker-payload, connecting a monoclonal antibody to a potent cytotoxic agent, vinblastine. The antibody specifically targets cancer cells, ensuring the delivery of the cytotoxic payload directly to the tumor site. This targeted approach minimizes damage to healthy cells, reducing side effects compared to traditional chemotherapy. The Val-Cit-PAB segment is designed to be cleaved by enzymes within the cancer cells, releasing vinblastine to exert its anti-cancer effects. This mechanism enhances the precision and efficacy of the treatment, making it a promising option in oncology.